Inclusion Criteria:

• Histologically verified gastric carcinoma of advanced stages which is unsuitable for surgery;
• No prior systemic chemotherapy with taxane at least 6 months before the recruitment;
• At least one measurable tumor according to RECIST standard, with at least one diameter ≥20mm assessed by traditional imaging technique or MRI, or with a diameter twice of the thickness of scan layer (or ≥10-16mm) under spiral CT; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;
• Patients who are expected to live at least 3 months;
• Obtaining informed consent;

Exclusion Criteria:

• Receiving other chemotherapy or radiotherapy during the administration;
• Symptomatic metastatic brain tumor;
• Allergy to any study medication;
• Pregnancy or breast feeding;
• Severe heart diseases;
• Uncontrolled mental diseases;
• Abnormal liver and renal functions, which are measured by AST/ALT and BUN/Cr;
• Neutrophils（ANC）<2000/μL;platelets<100，000/μL;hemoglobin（HB）<9.0 g/dL;